Peru

In Peru, the primary regulatory authority for health products, including pharmaceuticals, medical devices, diagnostics, and related technologies, is DIGEMID (Dirección General de Medicamentos, Insumos y Drogas), operating under the Ministerio de Salud (MINSA). The overarching legal framework is established by Ley N° 29459 (Ley de los Productos Farmacéuticos, Dispositivos Médicos y Productos Sanitarios) and its associated regulations, including Decreto Supremo N° 016-2011-SA for pharmaceuticals and Decreto Supremo N° 010-1997-SA for medical devices. All health products intended for commercialization in Peru must obtain a Registro Sanitario (sanitary registration) prior to market entry. The approval process involves submission of technical and administrative dossiers to DIGEMID, which conducts documentary review, and in some cases laboratory analysis, before granting registration. Risk-based classification applies to medical devices, broadly following international frameworks.

Applicants must appoint a local legal representative or a domiciled pharmaceutical company (droguería or empresa fabricante) registered with DIGEMID to act as the responsible local entity for all regulatory submissions and post-market obligations. Dossiers are generally expected to follow CTD (Common Technical Document) structure for pharmaceuticals, while device submissions require technical files aligned with ISO standards and, where applicable, CE marking or FDA clearance documentation as supporting evidence. Peru has pursued regulatory harmonization through PAN-AMERICAN frameworks and participates in PAHO initiatives. Notable recent reforms include the implementation of electronic submission portals (Mesa de Partes Virtual) and streamlined expedited pathways for products pre-approved by stringent regulatory authorities (SRAs) such as the FDA, EMA, Health Canada, and others recognized by DIGEMID, which can significantly reduce review timelines. Digital health products remain an emerging area, with regulatory guidance still evolving under MINSA oversight.

Public procurement of health products in Peru is centrally coordinated through MINSA and its procurement arm, CENARES (Centro Nacional de Abastecimiento de Recursos Estratégicos en Salud), which manages strategic acquisitions of pharmaceuticals, medical devices, and diagnostics for the national public health network. Procurement is governed by Ley N° 30225 (Ley de Contrataciones del Estado) and overseen by OSCE (Organismo Supervisor de las Contrataciones del Estado). National tenders (licitaciones públicas) and framework agreements (convenios marco) are the primary mechanisms for public sector supply, with publication and adjudication conducted through the SEACE (Sistema Electrónico de Contrataciones del Estado) platform. Regional health authorities (Gerencias Regionales de Salud) may conduct their own procurement processes for decentralized needs, creating a dual central-regional procurement dynamic. EsSalud (Seguro Social de Salud), Peru's social health insurance institution, operates its own independent procurement system and represents a significant additional public market channel.

The private sector in Peru constitutes a substantial portion of health product consumption, accessed through pharmaceutical distributors, retail pharmacy chains (such as InkaFarma and MiFarmacias), and private hospitals and clinics, with no mandatory local manufacturing preference for private channel access. Peru also receives support from international donor and multilateral organizations, including PAHO/WHO, UNICEF Supply Division, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and USAID-funded programs, particularly for communicable disease control, maternal health, and essential medicines. Products procured through these channels may follow the donor organization's own qualification and procurement standards (such as WHO Prequalification) rather than solely relying on national Registro Sanitario. Local manufacturing capacity remains limited, and there are no formalized domestic preference policies in public tender law equivalent to those in some other Latin American markets, though national strategic interest considerations may influence certain procurement decisions.